Sinovac Biotech Ltd. (SVA)

Sinovac Biotech Ltd. (SVA $0.00)
- $0.00 P/E (TTM): 6.66X
- View SVA Profile
- View Questions on SVA

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

AstraZeneca PLC (AZN $82.31)
- $82.31 P/E (TTM): 37.27X Cap: $256.98B
- View AZN Profile
- View Questions on AZN
Sinovac Biotech Ltd. (SVA $0.00)
- $0.00 P/E (TTM): 6.66X
- View SVA Profile
- View Questions on SVA

Q: Hi,
SVA & AZN are both in phase 3 of COVID-19 vaccine.
What are your thoughts about these companies?
Which one has the better financial ability to see the end of the vaccine development, approval and production of the vaccine (if their vaccine will prove itself successful).
Thanks,
Morris

Read Answer Asked by Morris on July 22, 2020